Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E1.95 EPS (ttm)0.65 Insider Own6.70% Shs Outstand2.68M Perf Week10.53%
Market Cap3.38M Forward P/E- EPS next Y-2.86 Insider Trans0.00% Shs Float2.50M Perf Month-22.22%
Income1.75M PEG- EPS next Q-1.41 Inst Own5.96% Short Float4.76% Perf Quarter-83.20%
Sales12.14M P/S0.28 EPS this Y-89.70% Inst Trans-0.73% Short Ratio0.48 Perf Half Y-63.50%
Book/sh-0.66 P/B- EPS next Y31.39% ROA19.78% Short Interest0.12M Perf Year-88.33%
Cash/sh2.94 P/C0.43 EPS next 5Y- ROE- 52W Range0.66 - 14.75 Perf YTD-64.02%
Dividend Est.- P/FCF0.55 EPS past 5Y61.51% ROI- 52W High-91.46% Beta1.22
Dividend TTM- Quick Ratio0.80 Sales past 5Y-40.00% Gross Margin99.88% 52W Low90.91% ATR (14)0.23
Dividend Ex-Date- Current Ratio0.80 EPS Y/Y TTM102.58% Oper. Margin-23.03% RSI (14)40.66 Volatility28.98% 13.47%
Employees17 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin14.39% Recom1.67 Target Price30.50
Option/ShortNo / No LT Debt/Eq- EPS Q/Q81.52% Payout- Rel Volume3.00 Prev Close0.97
Sales Surprise- EPS Surprise-11.76% Sales Q/Q- EarningsMay 14 AMC Avg Volume246.92K Price1.26
SMA20-3.56% SMA50-33.28% SMA200-65.65% Trades Volume739,548 Change29.90%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Jun-11-24 08:00AM
May-15-24 06:53AM
May-14-24 08:56PM
04:01PM Loading…
May-07-24 04:01PM
Apr-10-24 06:30AM
Apr-08-24 09:10AM
Apr-03-24 08:00AM
Mar-07-24 10:03AM
Mar-05-24 04:29PM
Feb-28-24 04:02PM
Dec-20-23 08:00AM
07:55AM Loading…
Nov-21-23 07:55AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
Aug-14-23 07:00PM
04:05PM Loading…
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
May-11-23 11:24AM
May-10-23 04:38PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
Aug-10-22 04:02PM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.